Surveillance — Post-Treatment Cancer Monitoring

In oncology, surveillance is a formal clinical strategy that encompasses scheduled physical examinations, laboratory assessments, and diagnostic imaging over an extended duration following curative-intent therapy. It represents the standard standard of care bridging active anticancer intervention and long-term survivorship.

Surveillance intervals are calibrated based on the biological behaviour and recurrence timelines of specific tumours. High-risk intervals, usually the initial two to five years post-treatment, feature more frequent assessments. Surveillance protocols also distinguish between active surveillance—where low-risk, indolent malignancies are closely monitored without immediate invasive therapy—and routine follow-up surveillance aimed at identifying asymptomatic recurrence early enough for salvage treatments.

Surveillance is a cornerstone of cancer care because detecting recurrence before clinical symptoms appear often broadens therapeutic options and improves survival outcomes. It provides an organised framework for monitoring late physical effects of treatment, such as cardiac dysfunction, neuropathy, or secondary cancers. Additionally, surveillance visits give patients structured opportunities to discuss emotional difficulties, cognitive changes, and lifestyle modifications that lower health risks. By adhering to recommended schedules, patients ensure their survivorship care remains proactive, evidence-based, and responsive to emerging health issues.

Surveillance incorporates imaging, blood tests, and physical examinations tailored to tumour biology. Biomarkers include serum prostate-specific antigen (PSA) for prostate cancer, CEA for bowel cancer, CA-125 for ovarian cancer, and alpha-fetoprotein (AFP) for testicular or liver cancers. Circulating tumour DNA (ctDNA) is an emerging liquid biopsy tool used to identify molecular residual disease. Imaging modalities such as mammograms, CT scans, MRIs, and ultrasounds are scheduled periodically according to clinical guidelines to verify remission status.

Surveillance protocols apply to nearly all cancers treated with curative intent. It is particularly prominent in colorectal cancer, where regular colonoscopies and blood tests are standard. In breast cancer, annual mammography is central to post-treatment surveillance. It is also vital in melanoma, lymphoma, prostate, and testicular cancers, where recurrences may occur within predictable timeframes. Furthermore, active surveillance is commonly used as a primary management strategy for low-risk localised prostate cancer and low-grade thyroid cancer to avoid immediate overtreatment.

Surveillance directly guides therapeutic decisions during remission. If surveillance tests indicate biochemical or radiographic recurrence, clinicians can initiate second-line systemic therapies, targeted drugs, or salvage radiotherapy before extensive disease spread occurs. Conversely, sustained normal surveillance findings confirm that further therapy remains unnecessary, allowing patients to avoid unnecessary medication toxicities. Surveillance also identifies long-term complications, prompting interventions such as hormone replacement, physical therapy, or supportive medications to manage persistent post-treatment side effects.